Circulating tumour cells & circulating tumour DNA in patients with resectable colorectal liver metastases (MIRACLE): a prospective, observational biomarker study
Lissa Wullaert(Erasmus MC Cancer Institute), Hendrikus J. Dubbink(Erasmus MC), Maarten Vermaas(Association of British Orchestras), Ninos Ayez, Corine M. Beaufort(Erasmus MC Cancer Institute), Kelly R. Voigt(Erasmus MC Cancer Institute), Elisabeth M. Jongbloed(Erasmus MC Cancer Institute), Mai N. Van(Erasmus MC), Diederik J. Höppener(Erasmus MC Cancer Institute), Vanja de Weerd(Erasmus MC), Boris Galjart, Yannick Meyer(Erasmus MC Cancer Institute), Pascal G. Doornebosch(IJsselland Ziekenhuis), Eric J.T. Belt(Albert Schweitzer Ziekenhuis), Stefan Sleijfer(Erasmus MC Cancer Institute), Saskia M. Wilting(Amsterdam UMC Location Vrije Universiteit Amsterdam), Stavros Makrodimitris(Erasmus MC), Khrystany T. Isebia(Erasmus MC Cancer Institute), Pauline A.J. Mendelaar(Erasmus MC), Joost van der Hoeven, Paul D. Gobardhan(Amphia Ziekenhuis), John W.M. Martens(Erasmus MC), Noortje Verschoor, Jean Helmijr(Erasmus MC Cancer Institute), Dirk J. Grünhagen(Erasmus MC), Ronald van Marion(Erasmus MC), Arjen M. Rijken(Amphia Ziekenhuis), Maurice P.H.M. Jansen(Erasmus MC Cancer Institute), Jaco Kraan(Erasmus MC Cancer Institute), Lindsay Angus(Erasmus MC), Henk M.W. Verheul(Erasmus MC Cancer Institute), Manouk K. Bos, Jan H. Wijsman(Amphia Ziekenhuis), Cornelis Verhoef, Peggy N. Atmodimedjo(Erasmus MC Cancer Institute), Eric P. van der Stok(Erasmus MC Cancer Institute)
Cited by 7
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795